Abstract
The purpose of research — improvement of treatment programs for chronic Epstein-Barr virus mono-infection and mixed with clamidiosis infection in frequently ill children with use of inosine pranobex (isoprinosine) and recombinant interferon-a2b (viferon). Clinical, serological and immunological examination of 116 patients aged from 3 to 6 years with chronic Epstein-Barr virus infection in the form of mono-infection (48) and mixed with clamidiosis infection (68) is conducted. In the complex therapy of 24 children with mono-infection and 42 patients with mixed infection, inosine pranobex in combination with recombinant interferon-a2b were included. In 24 patients with mono-infection and 26 children with mixed infection, using only recombinant interferon-a2b. In patients with monoinfection, multiorgan pathology (respiratory, lymphoproliferative, cardial, cerebral, arthralgiс syndromes) was found. During serological examination found markers of active Epstein-Barr virus infection (IgM to VСA, IgG to EA, a high level of IgG to EBNA). Changes of the immune status was associated with activation of immune system (increase of CD8, HLA-DR, CD16, IgA, IgM, IgG, metabolic activity of neutrophils) and its damage (reduction of CD3, CD4, CD25, CD20, interferon-a, interleukin-4, reserve possibilities of neutrophils metabolism, increase of CD95, circulating immune complexes). Development of mixed infection led to a deepening of immunological disorders and increased frequency of respiratory, gastrointestinal and lymphoproliferative syndromes. When combined inosine pranobex and recombinant interferon-a2b was going to potentiation antiviral, of immunomodulatory and cytoprotective activity of drugs that reduced the incidence of acute respiratory infections and severity of multiorgan pathology. High efficiency and safety of inosine pranobex and recombinant interferon-a2b combination allow to recommend its inclusion in the complex therapy of patients from frequently ill children group with various forms of chronic Epstein-Barr virus infection.
Highlights
Цель исследования — совершенствование программы лечения хронической Эпштейна-Барр вирусной моно- и смешанной с хламидиозом микст-инфекции у часто болеющих детей с использованием инозина пранобекса и рекомбинантного интерферона-D2b
Changes of the immune status was associated with activation of immune system and its damage
When combined inosine pranobex and recombinant interferon-D2b was going to potentiation antiviral, of immunomodulatory and cytoprotective activity of drugs that reduced the incidence of acute respiratory infections and severity of multiorgan pathology
Summary
Эффективность комплексного использования инозина пранобекса и рекомбинантного интерферона-D при ХЭБВИ у ЧБД инфекции в результате поражения вирусом Эпштейна-Барр (ВЭБ) клеток иммунной системы (прежде всего, В-лимфоцитов) развивается иммунодефицитное состояние (ИДС), связанное с нарушением иммунного ответа по клеточному и гуморальному типам, функциональной активности факторов врожденной резистентности [4, 7, 8]. Маркова (2009) при использовании ИП в группе ЧБД выявила уменьшение частоты эпизодов ОРИ, положительную динамику показателей иммунного статуса — повышение количества CD3-, CD4-, CD16-, HLA-DR-лимфоцитов, содержания IgA, IgM, IgG, спонтанной и стимулированной хемилюминесценции нейтрофилов, продукции ИФНD и ИФНJ [31]. (2007) при использовании ИП у детей из группы ЧБД отметили уменьшение частоты ОРИ, улучшение иммунологических показателей, снижение активности герпесвирусов [37].
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
